Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model
Daniel C. Kirouac(University of Toronto), Saroja Ramanujan(Unknown), Shih-Min A. Huang(Novartis (Switzerland)), Mark Merchant(Revolution Medicines (United States)), Kapil Gadkar(Sea Turtle Conservancy), Gabriele Schaefer(Genesys (United States)), John G. Moffat(Biochemical Society), Jocelyn Chan(Genesys (United States)), Christine Orr(Exelixis (United States)), Lichuan Liu(Genesys (United States))
Cited by 65
Related Papers
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373
A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation
|Immunity|2005|317
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
|Proceedings of the National Academy of Sciences|2009|255